HomeCompareERYP vs PM

ERYP vs PM: Dividend Comparison 2026

ERYP yields 256.41% · PM yields 3.48%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ERYP wins by $541.17M in total portfolio value
10 years
ERYP
ERYP
● Live price
256.41%
Share price
$0.78
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$541.22M
Annual income
$306,262,465.48
Full ERYP calculator →
PM
Philip Morris International
● Live price
3.48%
Share price
$165.34
Annual div
$5.76
5Y div CAGR
17.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$2,492.02
Full PM calculator →

Portfolio growth — ERYP vs PM

📍 ERYP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodERYPPM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ERYP + PM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ERYP pays
PM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ERYP
Annual income on $10K today (after 15% tax)
$21,794.87/yr
After 10yr DRIP, annual income (after tax)
$260,323,095.66/yr
PM
Annual income on $10K today (after 15% tax)
$296.12/yr
After 10yr DRIP, annual income (after tax)
$2,118.22/yr
At 15% tax rate, ERYP beats the other by $260,320,977.44/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ERYP + PM for your $10,000?

ERYP: 50%PM: 50%
100% PM50/50100% ERYP
Portfolio after 10yr
$270.64M
Annual income
$153,132,478.75/yr
Blended yield
56.58%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PM right now

ERYP
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
1.9
Piotroski
2/9
PM
Analyst Ratings
17
Buy
7
Hold
1
Sell
Consensus: Buy
Price Target
$194.30
+17.5% upside vs current
Range: $180.00 — $205.00
Altman Z
4.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ERYP buys
0
PM buys
0
No recent congressional trades found for ERYP or PM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricERYPPM
Forward yield256.41%3.48%
Annual dividend / share$2.00$5.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17.2%
Portfolio after 10y$541.22M$49.6K
Annual income after 10y$306,262,465.48$2,492.02
Total dividends collected$516.37M$11.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: ERYP vs PM ($10,000, DRIP)

YearERYP PortfolioERYP Income/yrPM PortfolioPM Income/yrGap
1← crossover$36,341$25,641.03$11,648$408.29+$24.7KERYP
2$125,971$87,086.09$13,589$495.90+$112.4KERYP
3$416,912$282,122.92$15,877$603.21+$401.0KERYP
4$1,318,722$872,626.36$18,580$734.88+$1.30MERYP
5$3,990,640$2,579,607.07$21,781$896.75+$3.97MERYP
6$11,565,551$7,295,566.53$25,578$1,096.12+$11.54MERYP
7$32,135,691$19,760,551.21$30,092$1,342.17+$32.11MERYP
8$85,699,274$51,314,084.97$35,470$1,646.46+$85.66MERYP
9$219,589,910$127,891,686.63$41,892$2,023.58+$219.55MERYP
10$541,223,669$306,262,465.48$49,578$2,492.02+$541.17MERYP

ERYP vs PM: Complete Analysis 2026

ERYPStock

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.

Full ERYP Calculator →

PMConsumer Staples

Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 71 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full PM Calculator →
📬

Get this ERYP vs PM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ERYP vs SCHDERYP vs JEPIERYP vs OERYP vs KOERYP vs MAINERYP vs MOERYP vs BTIERYP vs PEP

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.